Skip to main content
Psychedex

6Node page

what any key link opens

psx:substance/4-aco-dmt/src/doi:10.3390/life13122345

src2026-09-24recordconsumed

derived from · upstream

none recorded

feeds · downstream

Closure of psx:substance/4-aco-dmt/src/doi:10.3390/life13122345: 27 upstream, 85 downstream.

psx:substance/4-aco-dmt/src/doi:10.3390/life13122345
  ├─ used  src/doi:10.1021/acsptsci.2c00177  Structure-Activity Relationships for Psilocybin, Baeocystin, Aeruginascin, and Related Analogues to Produce Pharmacological Effects in Mice
  ├─ used  src/doi:10.1002/dta.3255  Tentative identification of in vitro metabolites of O-acetylpsilocin (psilacetin, 4-AcO-DMT) by UHPLC-Q-Orbitrap MS
  ├─ used  src/doi:10.1055/s-1999-3490  Improvements to the Synthesis of Psilocybin and a Facile Method for Preparing the O-Acetyl Prodrug of Psilocin
  ├─ used  src/doi:10.1016/j.neulet.2023.137597  Rewarding Effects of the Hallucinogen 4-AcO-DMT Administration and Withdrawal in Rats: A Challenge to the Opponent-Process Theory
  ├─ used  src/doi:10.1007/s00204-026-04365-4  In-silico toxicity study of tryptamine, psilocin, psilocybin, N,N-dimethyltryptamine, 5'-methoxy-N,N-dimethyltryptamine and O-acetylpsilocin
  ├─ used  src/doi:10.1021/acsptsci.2c00222  Receptor Binding Profiles for Tryptamine Psychedelics and Effects of 4-Propionoxy-N,N-dimethyltryptamine in Mice
  ├─ used  src/url:7a90964f24ed4f5d  4-AcO-DMT (Psilacetin) - Erowid Basics
  ├─ used  src/url:946c31199207c835  4-AcO-DMT
  ├─ used  src/doi:10.1107/s2056989019007370  Bis(4-acetoxy-N,N-dimethyltryptammonium) fumarate: a new crystalline form of psilacetin, an alternative to psilocybin as a psilocin prodrug
  ├─ used  src/doi:10.3389/fpsyt.2023.1303365  In vivo validation of psilacetin as a prodrug yielding modestly lower peripheral psilocin exposure than psilocybin
  ├─ used  src/doi:10.1111/1556-4029.15167  Psilocin - The 'real deal' or an extraction byproduct
  ├─ used  src/doi:10.1007/7854_2017_475  Chemistry and Structure-Activity Relationships of Psychedelics.
  ├─ used  src/doi:10.1016/j.cell.2020.08.024  Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin Receptor
  ├─ used  src/doi:10.1007/s00204-024-03952-7  Elucidating the Phase I metabolism of psilocin in vitro
  ├─ used  src/doi:10.3390/pharmaceutics17040411  Pharmacokinetics of Psilocybin: A Systematic Review
  ├─ used  src/doi:10.1007/s40262-024-01454-4  Clinical Pharmacokinetics of Psilocin After Psilocybin Administration: A Systematic Review and Post-Hoc Analysis
  ├─ used  src/doi:10.1016/j.neuron.2025.06.012  The polypharmacology of psychedelics reveals multiple targets for potential therapeutics
  ├─ used  src/doi:10.1111/bph.70307  5-HT2A receptors in the prelimbic cortex VIP-expressing interneurons: A mechanism for psychedelic-induced innate fear attenuation
  ├─ used  src/doi:10.1016/j.euroneuro.2016.05.001  Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens
  ├─ used  src/doi:10.3390/cimb45080427  Anti-Inflammatory Effects of Serotonin Receptor and Transient Receptor Potential Channel Ligands in Human Small Intestinal Epithelial Cells
  ├─ used  src/doi:10.1007/s00204-020-02693-7  Designer drugs: mechanism of action and adverse effects
  ├─ used  src/doi:10.3390/brainsci8030047  Hallucinogen Persisting Perception Disorder: Etiology, Clinical Features, and Therapeutic Perspectives
  ├─ used  src/doi:10.3389/fphar.2017.00423  A Single Dose of LSD Does Not Alter Gene Expression of the Serotonin 2A Receptor Gene (HTR2A) or Early Growth Response Genes (EGR1-3) in Healthy Subjects
  ├─ used  src/doi:10.1016/j.celrep.2023.112203  A non-hallucinogenic LSD analog with therapeutic potential for mood disorders
  ├─ used  src/pmid:16051647  Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.
  ├─ used  src/doi:10.1007/s40263-025-01256-7  Safety and Efficacy of Monoamine Oxidase Inhibitors in Patients Who Use Psychoactive Substances
  └─ generated_by  pub/9aa9e7e9-e7aa-40c4-b484-d5fa3248e35f  Publication — backfill
├─ used  version/1  Revision 1
├─ used  claim/7f488a1d-c2bc-430b-b502-d012adddd73a  Claim in receptor-pharmacology — supported
  ├─ derived_from  issue/notice@b90cab31cadf  Issued notice
  ├─ derived_from  issue/info_card@2b6c0a7b280e  Issued info_card
  ├─ derived_from  issue/emergency@3f0909c25c71  Issued emergency
  ├─ derived_from  issue/notice@9a96b1160ba9  Issued notice
  ├─ derived_from  issue/info_card@017f70fc6826  Issued info_card
  ├─ derived_from  issue/emergency@c15c760aabf6  Issued emergency
  ├─ informed_by  section/receptor-pharmacology.full@1
    ├─ used  claim/3617354c-493e-4341-bb74-24bc8d3dd21c  Claim in summary — supported
    ├─ used  claim/d9ce289b-3fac-409f-b14d-b718b6080e3f  Claim in pharmacology — supported
    ├─ used  claim/e478bf38-094d-4fad-bc17-ac5ed8ed3a55  Claim in chemistry — inconclusive  working
    ├─ used  claim/52d0ee3d-6868-4a61-9c92-ebd19e022f15  Claim in chemistry — inconclusive  working
    ├─ used  claim/0fb0121c-5009-416c-9c8c-c7a5ee68b425  Claim in clinical-evidence — supported
    ├─ used  claim/b25d9ff3-863f-4ab3-a3e4-afa024fcf0ae  Claim in comparative-pharmacology — supported
    ├─ used  claim/eaae7ee1-b8f0-44ed-851d-c556678e655c  Claim in comparative-pharmacology — inconclusive  working
    ├─ used  claim/c05aa42c-ac1e-4997-b1c7-9b09da78980b  Claim in summary — supported
    ├─ used  claim/3f7cc258-d1ec-4e95-bfac-0ed5ce1783b8  Claim in pharmacology — supported
    ├─ used  claim/dd88e857-8427-4211-b938-c7f622a31ec7  Claim in pharmacology — supported
    ├─ used  claim/2b9b3a2b-b8a1-4f10-ab03-76ae6b6203c5  Claim in pharmacology — inconclusive  working
    ├─ used  claim/6d01ed86-77db-41e0-8784-2ec91c09e019  Claim in pharmacology — supported
    ├─ used  claim/65e8ce5d-f204-4d39-9ee6-dfe1d10ad7af  Claim in history — supported
    ├─ used  claim/31b050c2-db3b-4d9e-9c99-16e12954691d  Claim in chemistry — supported
    ├─ used  claim/c7280ee1-74df-4692-94e2-ff56b7365a69  Claim in pharmacokinetic-detail — inconclusive  working
    ├─ used  claim/be9dc055-82f6-4975-bce4-4a7093aaa9e8  Claim in summary — inconclusive  working
    ├─ used  claim/c6649a03-8204-407a-9b02-70c302634a9f  Claim in history — inconclusive  working
    ├─ used  claim/8950b9b2-437c-484d-9d02-0ade92aa1b36  Claim in clinical-evidence — inconclusive  working
    ├─ used  claim/3d1e478c-9501-4f1f-b62a-5720a25da6e0  Claim in summary — supported
    ├─ used  claim/b94dc1de-29e5-4570-8290-80ccfc41ccea  Claim in safety — supported
    ├─ used  claim/8ce5caf4-3bd0-4038-b8be-31f2ef1c2ee1  Claim in summary — supported
    ├─ used  claim/5adcc309-1144-4739-93f0-49abbf43c177  Claim in safety — supported
    ├─ used  claim/c626184b-f24c-4fd4-ab58-e31874e88845  Claim in safety — inconclusive  working
    ├─ used  claim/54a78cdf-4e10-4f50-9d10-303ac85afe4f  Claim in summary — inconclusive  working
    ├─ used  claim/e9058156-ed38-4fb6-bded-a0ff45169554  Claim in pharmacology — inconclusive  working
    ├─ used  claim/0985b16c-2ceb-4d03-b969-e974fcc2b3ab  Claim in history — inconclusive  working
    ├─ used  claim/e86c8e89-6a23-4a84-8474-5b5a5e30ad1c  Claim in receptor-pharmacology — inconclusive  working
    ├─ used  claim/8eb7ef5e-d5fa-4a3d-9f62-dd19c24812de  Claim in receptor-pharmacology — inconclusive  working
    ├─ used  claim/c817495f-7b81-4865-8bb7-ea1603549af6  Claim in comparative-pharmacology — inconclusive  working
    ├─ used  claim/5131d7b3-83dc-4f23-a280-65734b4c067e  Claim in history — supported
    ├─ used  claim/185b139f-3bfd-494a-a266-0ae634b2f854  Claim in chemistry — supported
    ├─ used  claim/a1931c29-e085-43a0-854c-a643629bdd04  Claim in pharmacology — supported
    ├─ used  claim/a4e5c24d-9833-4626-9fc2-17480de00a81  Claim in pharmacology — supported
    ├─ used  claim/26c749eb-394a-424f-ac3a-2f768edceea6  Claim in history — supported
    ├─ used  claim/abc4973f-18e2-49d4-b628-b4946444a58a  Claim in chemistry — supported
    ├─ used  claim/fcd3b5f9-5cdb-4a5d-9f7c-aef907ee80a5  Claim in pharmacokinetic-detail — supported
    ├─ used  claim/df9f36ff-5a48-4bbc-bd16-7b84d9d7c9f3  Claim in comparative-pharmacology — supported
    ├─ used  claim/27ba8da7-31c1-46e9-8465-075aac98bb43  Claim in pharmacokinetic-detail — supported
    ├─ used  claim/c1d6a93c-daba-4248-95ec-80cbcc853720  Claim in pharmacokinetic-detail — supported
    ├─ used  claim/550e91ac-8658-40b3-8428-aebc20c8ca9f  Claim in pharmacology — inconclusive  working
    ├─ used  claim/ff3f3dfc-0129-4863-8282-c15d5e46c69c  Claim in safety — inconclusive  working
    ├─ used  claim/f894156e-b5ac-4d13-958d-46d48eceeb4c  Claim in chemistry — inconclusive  working
    ├─ used  claim/b0bbf754-f76b-41d1-a54b-f650a6ea8b75  Claim in pharmacology — inconclusive  working
    ├─ used  claim/58756367-b293-4f71-86aa-4baef8afad2b  Claim in pharmacology — inconclusive  working
    ├─ used  claim/017d8a68-0053-48fc-939e-7c5a7b596853  Claim in pharmacology — supported
    ├─ used  claim/44d7bb43-e7a6-487e-9798-522b526059c4  Claim in safety — supported
    ├─ used  claim/a5ee8056-ef18-4f6d-b46f-8838920c895f  Claim in safety — not_supported  working
    ├─ used  claim/3010606d-ab9b-461d-9cd2-d42aae4d1132  Claim in pharmacokinetic-detail — inconclusive  working
    ├─ used  claim/c5d57f99-a493-47d5-ac6e-6aa4c6722b0c  Claim in pharmacology — not_supported  working
    ├─ used  claim/a7fa3081-eb05-414f-96a6-66aaf72be87a  Claim in pharmacology — supported
    ├─ used  claim/8055509d-035d-4276-b4e2-578bc79a37c5  Claim in pharmacokinetic-detail — inconclusive  working
    ├─ used  claim/9b8f8caa-bf61-4028-9717-3c28894e6602  Claim in pharmacology — inconclusive  working
    ├─ used  claim/637b29ab-3b0b-455f-b45e-6595e483c936  Claim in pharmacokinetic-detail — inconclusive  working
    ├─ used  claim/b9b428a9-a36b-42e2-a06a-a4558a4e9a57  Claim in pharmacology — inconclusive  working
    ├─ used  claim/7bd8cdaa-b105-4214-a097-86bb7cf574bb  Claim in receptor-pharmacology — inconclusive  working
    ├─ used  claim/b0b366c1-681e-4f20-bac0-8d601f12b16a  Claim in neuroscience — supported
    ├─ used  claim/821945f9-2270-480a-b99e-fd3fcb92a9cc  Claim in receptor-pharmacology — partially_supported
    ├─ used  claim/0fe71528-28d1-4e93-95bd-0c35037c9568  Claim in safety — inconclusive  working
    ├─ used  claim/6cddc844-8d72-4c45-83a5-abf4d8bfd458  Claim in safety — supported
    ├─ used  claim/f283917e-d2bc-48b6-96ea-93f5272cabb6  Claim in safety — inconclusive  working
    ├─ used  claim/98aafcb6-7ddc-4faa-b4c7-5cd180683323  Claim in safety — partially_supported
    ├─ used  claim/2d58d95d-b4d6-4837-a2a2-bd7d4c2caed4  Claim in safety — inconclusive  working
    ├─ used  claim/26c584ca-5ec7-49d9-9985-99a234914111  Claim in safety — inconclusive  working
    ├─ used  claim/166872ec-86ef-471d-ba5d-44f41f7855b8  Claim in safety — inconclusive  working
    ├─ used  claim/1d679b3b-9329-4d92-a2c3-eeb3c6d360e1  Claim in safety — inconclusive  working
    ├─ used  claim/36ce5222-048e-4736-af2c-503cda399548  Claim in safety — inconclusive  working
    ├─ used  claim/504f08c2-e559-403a-86b8-e8fd85940862  Claim in safety — inconclusive  working
      ├─ informed_by  section/summary.full@1
      ├─ informed_by  section/pharmacology.full@1
      ├─ informed_by  section/chemistry.full@1
      ├─ informed_by  section/clinical-evidence.full@1
      ├─ informed_by  section/comparative-pharmacology.full@1
      ├─ informed_by  section/history.full@1
      ├─ informed_by  section/pharmacokinetic-detail.full@1
      ├─ informed_by  section/safety.full@1
      └─ informed_by  section/neuroscience.full@1

indented by distance from this node, not by parentage

1Provenance card

the boundary, as counts

Sources

2724 with DOI

16 strong · 9 moderate · 2 weak

Compilations

0no compilation run

Decisions

42last ruled 2026-06-04

0 awaiting a ruling

Issued documents

62026-10-19T20:29:50.217Z

notice · info card · emergency

Searches

00 with no results

queries and counts on the build

Claims checked

6832 supported

32 supported · 36 not

Correspondence

0received

consent field ships in Phase 4

Edges

213

derivations recorded for this entity

Complete over 27 sources and 42 decisions.Not here: the private journal (never).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/4-aco-dmt/archive

3Sources

27 consumed · sorted by year · feeds = sections resting on it

Sources
yearsourcetierstatusfeeds
20265-HT2A receptors in the prelimbic cortex VIP-expressing interneurons: A mechanism for psychedelic-induced innate fear attenuationWang Y, Yao Y, Su R, Yan H · British Journal of Pharmacologydoi:10.1111/bph.70307moderateconsumed1 section
2026In-silico toxicity study of tryptamine, psilocin, psilocybin, N,N-dimethyltryptamine, 5'-methoxy-N,N-dimethyltryptamine and O-acetylpsilocinJurowski K, Kobylarz D, Noga M · Archives of Toxicologydoi:10.1007/s00204-026-04365-4moderateconsumed2 sections
2026Safety and Efficacy of Monoamine Oxidase Inhibitors in Patients Who Use Psychoactive SubstancesRached G, Campana A, Fiani D, et al. · CNS Drugsdoi:10.1007/s40263-025-01256-7strongconsumed1 section
2025Clinical Pharmacokinetics of Psilocin After Psilocybin Administration: A Systematic Review and Post-Hoc AnalysisOtto ME, van der Heijden KV, Schoones JW, et al. · Clinical Pharmacokineticsdoi:10.1007/s40262-024-01454-4strongconsumed2 sections
2025Elucidating the Phase I metabolism of psilocin in vitroChen J, Wang Z, Yong CY, et al. · Archives of Toxicologydoi:10.1007/s00204-024-03952-7moderateconsumed3 sections
2025Pharmacokinetics of Psilocybin: A Systematic ReviewMeshkat S, Al-Shamali H, Perivolaris A, et al. · Pharmaceuticsdoi:10.3390/pharmaceutics17040411strongconsumed2 sections
2025The polypharmacology of psychedelics reveals multiple targets for potential therapeuticsJain MK, Gumpper RH, Slocum ST, Schmitz GP, Madsen JS, Tummino TA, Suomivuori CM, Huang XP, Shub L, DiBerto JF, Kim K, DeLeon C, Krumm BE, Fay JF, Keiser M, Hauser AS, Dror RO, Shoichet B, Gloriam DE, Nichols DE, Roth BL · Neurondoi:10.1016/j.neuron.2025.06.012strongconsumed2 sections
20244-AcO-DMTWikipedia contributorsurl:946c31199207c835weakconsumedcited only
2024In vivo validation of psilacetin as a prodrug yielding modestly lower peripheral psilocin exposure than psilocybinJones NT, Wagner L, Hahn MCP, Scarlett CO, Wenthur CJ · Frontiers in Psychiatrydoi:10.3389/fpsyt.2023.1303365strongconsumed5 sections
2024Rewarding Effects of the Hallucinogen 4-AcO-DMT Administration and Withdrawal in Rats: A Challenge to the Opponent-Process TheoryVargas-Perez H, Minauro-Sanmiguel F, Ting-A-Kee R, Grieder TE, Méndez-Díaz M, Próspero-García O, van der Kooy D · Neuroscience Lettersdoi:10.1016/j.neulet.2023.137597strongconsumed2 sections
2023A non-hallucinogenic LSD analog with therapeutic potential for mood disordersLewis V, Bonniwell EM, Lanham JK, Ghaffari A, Sheshbaradaran H, Cao AB, Calkins MM, Bautista-Carro MA, Arsenault E, Telfer A, Taghavi-Abkuh FF, Malcolm NJ, El Sayegh F, Abizaid A, Schmid Y, Morton K, Halberstadt AL, Aguilar-Valles A, McCorvy JD · Cell Reportsdoi:10.1016/j.celrep.2023.112203strongconsumed1 section
2023Anti-Inflammatory Effects of Serotonin Receptor and Transient Receptor Potential Channel Ligands in Human Small Intestinal Epithelial CellsRobinson GI, Li D, Wang B, Zahoruiko Y, Gerasymchuk M, Hudson D, Kovalchuk O, Kovalchuk I · Current Issues in Molecular Biologydoi:10.3390/cimb45080427moderateconsumedcited only
2023Psilocin - The 'real deal' or an extraction byproductGutman O, Tenne D, Bretler U · Journal of Forensic Sciencesdoi:10.1111/1556-4029.15167moderateconsumed1 section
2023Psilocybin and Eugenol Reduce Inflammation in Human 3D EpiIntestinal TissueRobinson GI, Li D, Wang B, Rahman T, Gerasymchuk M, Hudson D, Kovalchuk O, Kovalchuk I · Lifedoi:10.3390/life13122345moderateconsumed1 section
2023Receptor Binding Profiles for Tryptamine Psychedelics and Effects of 4-Propionoxy-N,N-dimethyltryptamine in MiceGlatfelter GC, Naeem M, Pham DNK, Golen JA, Chadeayne AR, Manke DR, Baumann MH · ACS Pharmacology & Translational Sciencedoi:10.1021/acsptsci.2c00222strongconsumed5 sections
2022Structure-Activity Relationships for Psilocybin, Baeocystin, Aeruginascin, and Related Analogues to Produce Pharmacological Effects in MiceGlatfelter GC, Pottie E, Partilla JS, Sherwood AM, et al. · ACS Pharmacology and Translational Sciencedoi:10.1021/acsptsci.2c00177moderateconsumed5 sections
2022Tentative identification of in vitro metabolites of O-acetylpsilocin (psilacetin, 4-AcO-DMT) by UHPLC-Q-Orbitrap MSZhai W, Li L, Zhao J, Xiang P, Liu M, Shi Y, Dang Y · Drug Testing and Analysisdoi:10.1002/dta.3255strongconsumed5 sections
2020Designer drugs: mechanism of action and adverse effectsLuethi D, Liechti ME · Archives of Toxicologydoi:10.1007/s00204-020-02693-7strongconsumed1 section
2020Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin ReceptorKim K, Che T, Panova O, DiBerto JF, Lyu J, Krumm BE, Wacker D, Robertson MJ, Seven AB, Nichols DE, Shoichet BK, Skiniotis G, Roth BL · Celldoi:10.1016/j.cell.2020.08.024strongconsumed1 section
2019Bis(4-acetoxy-N,N-dimethyltryptammonium) fumarate: a new crystalline form of psilacetin, an alternative to psilocybin as a psilocin prodrugChadeayne AR, Golen JA, Manke DR · Acta Crystallographica Section E Crystallographic Communicationsdoi:10.1107/s2056989019007370strongconsumed2 sections
2018Chemistry and Structure-Activity Relationships of Psychedelics.Nichols DE · Current Topics in Behavioral Neurosciencesdoi:10.1007/7854_2017_475strongconsumed3 sections
2018Hallucinogen Persisting Perception Disorder: Etiology, Clinical Features, and Therapeutic PerspectivesMartinotti G, Santacroce R, Pettorruso M, Montemitro C, Spano MC, Lorusso M, Di Giannantonio M, Gallimberti L · Brain Sciencesdoi:10.3390/brainsci8030047moderateconsumed1 section
2017A Single Dose of LSD Does Not Alter Gene Expression of the Serotonin 2A Receptor Gene (HTR2A) or Early Growth Response Genes (EGR1-3) in Healthy SubjectsDolder PC, Grünblatt E, Müller F, Borgwardt SJ, Liechti ME · Frontiers in Pharmacologydoi:10.3389/fphar.2017.00423strongconsumed1 section
20164-AcO-DMT (Psilacetin) - Erowid BasicsErowidurl:7a90964f24ed4f5dweakconsumedcited only
2016Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogensRickli A, Moning OD, Hoener MC, Liechti ME · European Neuropsychopharmacologydoi:10.1016/j.euroneuro.2016.05.001strongconsumed1 section
2005Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.Gillman PK · British Journal of Anaesthesiapmid:16051647strongconsumed1 section
1999Improvements to the Synthesis of Psilocybin and a Facile Method for Preparing the O-Acetyl Prodrug of PsilocinNichols DE, Frescas S · Synthesisdoi:10.1055/s-1999-3490moderateconsumed3 sections

4Docket

one filing per activity — decisions, correspondence, reports

  1. 0012026-04-19revisionRevision 1

    Initial LLM generation (v5 pipeline, wiki)

    psx:substance/4-aco-dmt/version/1
  2. 0022026-06-04proposal40 value proposals approved together

    one review action inferred from a shared reviewer and instant — the graph records one activity per proposal

    40 items in this filing

    • dose_tier · light
    • dose_tier · common
    • dose_tier · strong
    • dose_tier · heavy
    • timeline · oral · onset
    • timeline · oral · come_up
    • timeline · oral · peak
    • timeline · oral · resolution
    • timeline · oral · afterglow
    • timeline · insufflated · onset
    • timeline · insufflated · come_up
    • timeline · insufflated · peak
    • timeline · insufflated · resolution
    • timeline · insufflated · afterglow
    • toxicity
    • dependence · full
    • withdrawal
    • tolerance
    • dosage · oral
    • dosage · insufflated
    • duration · oral · onset
    • duration · oral · come_up
    • duration · oral · peak
    • duration · oral · offset
    • duration · oral · total
    • duration · oral · aftereffects
    • duration · insufflated · onset
    • duration · insufflated · come_up
    • duration · insufflated · peak
    • duration · insufflated · offset
    • duration · insufflated · total
    • duration · insufflated · aftereffects
    • contraindication · psychiatric
    • contraindication · psychiatric
    • contraindication · other
    • contraindication · other
    • contraindication · cardiovascular
    • contraindication · neurological
    • contraindication · pregnancy_breastfeeding
    psx:substance/4-aco-dmt/proposal/dose_tier/343ef73e-f797-4471-b512-4c292aa90f76
  3. 0032026-06-04publicationPublication — backfill
    psx:substance/4-aco-dmt/pub/9aa9e7e9-e7aa-40c4-b484-d5fa3248e35f

5Issued documents

what the notice, info card and emergency page said, by hash

Issued documents
documentcontent hashissuedfrom versionsuperseded
emergencyc15c760aabf6f0fcf5b6fc6b…2026-10-19 20:29Revision 1current
info_card017f70fc6826ea42f871be74…2026-10-19 20:29Revision 1current
notice9a96b1160ba9098f7cde020c…2026-10-19 20:29Revision 1current
emergency3f0909c25c714d225b4bb3e3…2026-09-04 04:27Revision 1superseded2026-10-19
info_card2b6c0a7b280ef371daca87c7…2026-09-04 04:27Revision 1superseded2026-10-19
noticeb90cab31cadf5bd920a3dc6c…2026-09-04 04:27Revision 1superseded2026-10-19